Seaport Therapeutics rakes in $100m for neuropsychiatric medicine advancement
Seaport Therapeutics, a pioneering clinical-stage biopharmaceutical company, has successfully closed an oversubscribed Series A financing round, securing $100 million. This significant milestone was led by ARCH Venture Partners and Sofinnova Investments, in collaboration with Third Rock Ventures and Seaport founder PureTech Health. This financial injection is earmarked for the accelerated development of Seaport’s clinical-stage pipeline […]